These press releases remain on AbbVie's website for historical purposes only. Long-term Ubrelvy trial data showed that in addition to effectively treating migraine attacks when pain is moderate or severe, treating when pain is mild may significantly increase rates of pain freedom and absence of migraine-associated symptoms. The combined company's 2020 adjusted diluted EPS guidance excludes $6.23 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items. The Phase 3 VIALE-A trial demonstrated that previously untreated patients with AML who were ineligible for intensive chemotherapy treated with Venclexta plus azacitidine achieved a 34 percent reduction in the risk of death compared to azacitidine in combination with placebo. The adjusted SG&A expense was 22.9 percent of net revenues. On a GAAP basis, the gross margin ratio in the second quarter was 64.4 percent. Refer to the Quarterly Comparable Historical Trend Analysis for additional information regarding comparable historical net revenues. Readers should not rely upon the information in these pages as current or accurate after their publication dates. 1. Comparable historical net revenues include total revenues for all reported periods for both AbbVie and Allergan products as if the acquisition closed on January 1, 2019. We also welcome the opportunity to hear from you in these social channels, but remember we work in a highly-regulated industry with unique legal considerations. Comparing ABBV-3373 to combined in-trial and historical adalimumab data, based on a Bayesian analysis, predicted with a 90 percent probability that ABBV-3373 was associated with a greater improvement on DAS28-CRP from baseline to week 12 than adalimumab. One of these very few stocks left which offer such a profile is healthcare large-cap AbbVie, a stock which had a disastrous 2019. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn. Sign up Additionally, more patients treated with Rinvoq plus TCS experienced a clinically meaningful reduction in itch compared to patients treated with placebo plus TCS and treatment with either dose of Rinvoq led to a higher mean number of TCS-free days. Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. The cash dividend is payable November 16, 2020 to stockholders of record at the close of business on October 15, 2020.. Follow @abbvie on Twitter, Facebook or LinkedIn. AbbVie plans to meet with the FDA and EMA to discuss their comments and determine next steps. Represents net earnings (loss) attributable to AbbVie Inc. Acquisition related costs reflect transaction, financing and integration costs related to the Allergan acquisition as well as amortization of the acquisition date fair value step-up for inventory. Diluted EPS in the second quarter was a loss of. Refer to the Quarterly Comparable Historical Trend Analysis for additional information regarding comparable historical net revenues. Juvederm Voluma XC is the first and only filler to receive FDA approval for the augmentation of the chin region and this latest approval marks the Juvederm Collection's fifth approved indication in the U.S. AbbVie announced that the Phase 3 ADVANCE trial evaluating atogepant, an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist, met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to placebo, for all doses (10mg, 30mg, or 60mg) across the 12-week treatment period. - On May 8, 2020, AbbVie Completed its Acquisition of Allergan, Significantly Expanding and Diversifying AbbVie's Revenue Base with New Therapeutic Areas, Enhancing Long-Term Growth Potential, and Enabling Investment in Innovation for each of its Therapeutic Categories. | The trial also demonstrated that treatment with 30mg and 60mg doses resulted in statistically significant improvements in all secondary endpoints, including ≥ 50% reduction in three-month average of monthly migraine days, improvements in acute medication use, and performance of daily activities and physical impairment. Follow us on social media. Excluding items, AbbVie earned $2.21 per share in the fourth quarter, edging past expectations by 2 cents. If you qualify, please, https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/. | Restructuring is primarily associated with streamlining global operations. Click to Tweet: Student scholars living with #cysticfibrosis need your help! The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in AbbVie Inc. for potential breaches of fiduciary duty on the... | October 11, 2020 3. Sep 04, 2020. It is now time to look forward and see how the new AbbVie will be performing. AbbVie is a research-based global biopharmaceutical company committed to developing innovative, advanced therapies for some of the world’s most complex and critical conditions. I started singing early on and now I am pursuing a degree in music," said Sean Dean, 2019 AbbVie CF Scholarship Thriving Undergraduate Student. AbbVie assumes no duty to update the information to reflect subsequent developments. AbbVie is hoping to maintain its leadership position in the $70 billion global immunology market dominated by Humira, which treats both rheumatoid arthritis and psoriasis, as well as several related autoimmune conditions. "Comparable Operational" comparisons include full-quarter current year and prior year results for Allergan, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. Overall, the safety profile of Rinvoq in PsA was consistent with previously reported results across the Phase 3 rheumatoid arthritis (RA) clinical trial program, with no new significant safety risks detected. About the AbbVie CF ScholarshipThe AbbVie CF Scholarship was established 28 years ago in recognition of the financial burdens many families touched by CF face and to acknowledge the achievements of students with CF. AbbVie said it expects 2020 adjusted earnings of $9.61 to $9.71 per share, above analysts’ estimates of $9.48. YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE. Since its inception, the scholarship program has awarded over $3.3 million in scholarships to over 1,000 students. NORTH CHICAGO, Ill., July 31, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2020. Revenue rose 4.8% to $8.70 billion, in line with the average analysts’ estimate of $8.69 billion. The adjusted tax rate for the second quarter of 2019 was 8.7 percent, as detailed below: Acquisition related costs reflect transaction, financing and integration costs related to the Allergan acquisition as well as amortization of the acquisition date fair value step-up for inventory. Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics.